Liminal Biosciences Inc

-0.01 (-2.88%)
Earnings Announcements

Liminal BioSciences Reports First Quarter 2022 Results

Published: 05/10/2022 21:38 GMT
Liminal Biosciences Inc (LMNL) - Liminal Biosciences Reports First Quarter 2022 Financial Results and Business Highlights.
Liminal Biosciences - Cash Was $61.2 Million at March 31, 2022 While Our Working Capital, Ie, Current Assets Net of Current Liabilities, Was $42.7 Million.
Liminal Biosciences Inc - Net Loss of $11.2 Million During Quarter Ended March 31, 2022.
Revenue is expected to be $0.15 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0.56 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.